Development of Pandemic Vaccines: ERVEBO Case Study
Open Access
- 25 February 2021
- Vol. 9 (3), 190
- https://doi.org/10.3390/vaccines9030190
Abstract
Preventative vaccines are considered one of the most cost-effective and efficient means to contain outbreaks and prevent pandemics. However, the requirements to gain licensure and manufacture a vaccine for human use are complex, costly, and time-consuming. The 2013–2016 Ebola virus disease (EVD) outbreak was the largest EVD outbreak to date and the third Public Health Emergency of International Concern in history, so to prevent a pandemic, numerous partners from the public and private sectors combined efforts and resources to develop an investigational Zaire ebolavirus (EBOV) vaccine candidate (rVSVΔG-ZEBOV-GP) as quickly as possible. The rVSVΔG-ZEBOV-GP vaccine was approved as ERVEBOTM by the European Medicines Authority (EMA) and the United States Food and Drug Administration (FDA) in December 2019 after five years of development. This review describes the development program of this EBOV vaccine, summarizes what is known about safety, immunogenicity, and efficacy, describes ongoing work in the program, and highlights learnings applicable to the development of pandemic vaccines.Keywords
Funding Information
- Merck (n/a)
This publication has 44 references indexed in Scilit:
- A Recombinant Vesicular Stomatitis Virus Ebola VaccineThe New England Journal of Medicine, 2017
- Antibodies are necessary for rVSV/ZEBOV-GP–mediated protection against lethal Ebola virus challenge in nonhuman primatesProceedings of the National Academy of Sciences of the United States of America, 2013
- Animal models for Ebola and Marburg virus infectionsFrontiers in Microbiology, 2013
- Licensure of vaccines using the Animal RuleCurrent Opinion in Virology, 2012
- Recombinant Vesicular Stomatitis Virus Vaccine Vectors Expressing Filovirus Glycoproteins Lack Neurovirulence in Nonhuman PrimatesPLoS Neglected Tropical Diseases, 2012
- Single-Injection Vaccine Protects Nonhuman Primates against Infection with Marburg Virus and Three Species of Ebola VirusJournal of Virology, 2009
- Mucosal Immunization of Cynomolgus Macaques with the VSVΔG/ZEBOVGP Vaccine Stimulates Strong Ebola GP-Specific Immune ResponsesPLOS ONE, 2009
- Vesicular Stomatitis Virus-Based Ebola Vaccine Is Well-Tolerated and Protects Immunocompromised Nonhuman PrimatesPLoS Pathogens, 2008
- Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg virusesNature Medicine, 2005
- Properties of Replication-Competent Vesicular Stomatitis Virus Vectors Expressing Glycoproteins of Filoviruses and ArenavirusesJournal of Virology, 2004